mRNA-1893

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc.

Conditions

Zika Virus

Phase 1

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

CompletedNCT04064905

ModernaTX, Inc.Zika Virus

Start: 2019-07-30End: 2021-03-22Updated: 2024-08-21

Phase 2

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

CompletedNCT04917861

ModernaTX, Inc.Zika Virus

Start: 2021-06-07End: 2024-07-26Updated: 2025-09-25

Related Papers

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

2023-01-1997 citations